Hybio Pharmaceutical Co. Ltd. | |
Stock Exchange | Shenzhen Stock Exchange |
EPS |
CNY0.43 |
Market Cap |
CNY8.28 B |
Shares Outstanding |
571.46 M |
Public Float |
413.48 M |
Address |
4/F, Hybio Biomedical Park Office Shenzhen Guangdong 518057 China |
Employees | - |
Website | http://www.hybio.com.cn |
Updated | 07/08/2019 |
Hybio Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of polypeptide drugs. It offers Desmopressin acetate injection, Thymopentin, Somatostatin, Terlipressin, and Carbetocin for Injection. It focuses on building a digitalized chronic diseases management platform with the combination of drugs, medical instruments, and Internet. |